IRVINE, Calif., Feb. 1, 2006 (PRIMEZONE) -- "At the top of the list of President Bush's issues in last night's State of the Union address was a growing concern for health care amid the quickly aging demographic of the country," stated SmallCap Sentinel analyst D.R. Clark. "With Baby Boomers bringing the largest constituency of Americans ever to the health care industry, the president's concerns highlight the need for advancements in biotech, pharmaceutical and other aspects that contribute to the delivery of health care."
"It would seem obvious that this need would enhance opportunities for biotechnology companies to advance their products," said Clark. "As with any industry deluged with new and growing business, research and product development blossom amid the burgeoning need. I fully expect to see more interest in smaller companies developing imperative products for patients. Service to the baby boomer's needs will come from a host of providers."
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is available at www.SmallCapSentinel.com and will address stents and stent related companies including MIV Therapeutics, Inc. (OTCBB:MIVT), Angiotech Pharmaceuticals Inc. (Nasdaq:ANPI), Conor Medsystems Inc. (Nasdaq:CONR), and Guidant Corp. (NYSE:GDT). The report will place specific emphasis on drug eluting stents, their design, application, and imperative need.
MIV Therapeutics, Inc. is a developer of next-generation biocompatible stent coatings and drug delivery technologies for cardiovascular stents and for a broad range of implantable medical devices.
Interested parties may view additional information about MIVT via this direct link: http://www.trilogy-capital.com/tcp/mivt/factsheet.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen hundred dollars by MIV Therapeutics Corp. for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.